Paul J Maddon

This inventor holds 48 USPTO granted patents and 13 published patent applications, plus 4 CIPO patents and 5 EPO patents, primarily in HIV-1 Research. Top assignees: Progenics Pharmaceuticals, Inc., Columbia University, Psma Development Company, LLC. Active years: 1992-2019.

USPTO Granted Patents = 48 (Patent Applications = 13)

% Patents Active = 64.6

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 5 (Patent Applications = 7)

Average Co-Inventor Count = 3.0

ph-index = 14

Forward Citations = 480(Granted Patents)

Location History:

New York, NY (US) (1992 - 2008)
Elmsford, NY (US) (2000 - 2011)
Scarsdale, NY (US) (2004 - 2019)

Company Filing History:

32 out of 71

Progenics Pharmaceuticals, Inc.

Psma Development Company, LLC

patents

4. 2 out of 2

Aaron Diamond Aids Research Centre (Adarc)

Facet Biotech Corporation

patents

8. 2 out of 207

Smithkline Beckman Corporation

patents

9. 1 out of 1

Arogenics Pharmaceuticals, Inc.

11. 1 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2019

Loading Chart...

Areas of Expertise:

HIV-1

Anti-CCR5 Antibodies

Membrane Fusion Inhibition

Viral Load Reduction

PSMA Antibodies

CD4-GP120 Binding

DC-SIGN

Fusion Inhibitors

Nucleic Acids

Immunoconjugates

Hepatitis C Virus

T Cell Surface Proteins

48 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10500274 - Methods for reducing viral load in HIV-1 infected patients (2019-12-10),

2. 9695248 - PSMA antibodies and uses thereof (2017-07-04),

3. 8821877 - Methods for inhibiting HIV-1 replication involving the administration of an anti-CCR5 receptor monoclonal antibody and small molecule CCR5 receptor antagonist (2014-09-02),

4. 8470330 - PSMA antibodies and uses thereof (2013-06-25),

5. 8114965 - Compositions of PSMA antibodies (2012-02-14),

6. 7935797 - CCR5 chemokine receptor-specific monoclonal antibodies capable of inhibiting HIV-1 cell fusion (2011-05-03),

7. 7901685 - Methods for assaying inhibition of HIV-1 envelope glycoprotein-mediated membrane fusion (2011-03-08),

8. 7862994 - Methods for inhibiting HIV-1 envelope glycoprotein-medicated membrane fusion (2011-01-04),

9. 7858298 - Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists (2010-12-28),

10. 7851600 - Anti-CCR5 antibody (2010-12-14),

11. 7850971 - PSMA antibodies and protein multimers (2010-12-14),

12. 7736649 - Methods of inhibiting human immunodeficiency virus infection through the administration of synergistic combinations of anti-CCR5 monoclonal antibodies, fusion inhibitors, and CD4-GP120 binding inhibitors (2010-06-15),

13. 7666419 - Anti-CCR5 antibody (2010-02-23),

14. 7592014 - Stabilized viral envelope proteins and uses thereof (2009-09-22),

15. 7479553 - Nucleic acids encoding mutant disulfide bond-stabilized human immunodeficiency virus type 1 (HIV-1) gp140 envelope glycoproteins (2009-01-20),

Title: The Inventor Paul J Maddon: Pioneering Innovations in Scarsdale, NY

Introduction: Paul J Maddon is a distinguished inventor based in Scarsdale, NY, known for his groundbreaking contributions to various fields.

Latest Patents: Paul J Maddon holds several patents in the areas of technology and healthcare, showcasing his continuous commitment to innovation.

Career Highlights: With a career spanning over two decades, Paul J Maddon has been at the forefront of developing cutting-edge solutions that have revolutionized industries.

Collaborations: Throughout his career, Paul J Maddon has collaborated with leading experts, researchers, and institutions to further advance his inventions and bring them to market successfully.

Conclusion: Paul J Maddon's relentless pursuit of innovation and collaboration has solidified his position as a visionary inventor making significant strides in the world of technology and healthcare.